Understanding Youth Vaping Cessation and Cannabis Use

Young people who vape nicotine often use cannabis as well. This creates a challenge for parents and health professionals trying to help teens quit. A new study from Massachusetts General Hospital examined whether cannabis use makes it harder for adolescents to stop vaping nicotine. The research followed 261 young people aged 16 to 25. Around 72% of them reported using cannabis in the month before starting youth vaping cessation treatment.

The question matters because nicotine vaping has become the most common form of nicotine use amongst young people. Many develop regular use patterns. They experience withdrawal symptoms and failed quit attempts. Meanwhile, cannabis use is widespread in the same age group. Up to half of adolescents who vape nicotine also use cannabis.

My colleague recently told me about a 17-year-old who wanted to quit vaping but worried his cannabis use would sabotage his efforts. This new research suggests those fears might be unfounded, offering hope to young people facing similar struggles.

What the Research Revealed About Adolescent Nicotine Vaping Treatment

The study’s findings challenged common assumptions. Researchers discovered that baseline cannabis use did not significantly reduce the likelihood of successfully quitting nicotine vaping. This held true whether measured by frequency or severity of problematic use. Young people using cannabis occasionally had similar success rates to non-users.

The numbers tell an interesting story. Amongst those who reported no cannabis use, 33% achieved abstinence from nicotine vaping at 12 weeks. For those using cannabis up to four days weekly, the success rate was 44%. Even amongst daily or near-daily cannabis users (four to seven days per week), 29% successfully quit vaping nicotine. The differences between these groups were not statistically significant.

Treatment Effectiveness in Youth Vaping Cessation Programmes

The research found that varenicline proved equally effective regardless of cannabis use patterns. This medication helps people quit tobacco. Young people assigned to receive varenicline showed substantially higher quit rates than those receiving behavioural support alone. This benefit persisted across all levels of cannabis use.

The medication demonstrated remarkable effectiveness. Participants receiving varenicline were approximately 10 times more likely to achieve abstinence compared to those receiving other forms of support. This therapeutic benefit remained consistent. It applied whether participants used cannabis regularly or not at all. The statistical analysis showed no significant interaction between cannabis use and treatment response.

Why These Findings Matter for Adolescent Nicotine Vaping Treatment

This research challenges assumptions about cannabis use undermining nicotine cessation efforts. Any substance use carries risks for developing brains. However, these findings suggest that cannabis use need not be viewed as an insurmountable barrier to youth vaping cessation.

For families and professionals working with young people who vape, this represents an important consideration. The study indicates that effective treatment remains available and worthwhile. This applies even when multiple substance use patterns are present. The research involved 261 participants with a mean age of 21.5 years. Just over half (53%) were female. This provides a reasonably representative sample of young people facing these challenges.

The Broader Context of Adolescent Substance Use

The study also examined alcohol use. Researchers found no significant association between baseline alcohol consumption and vaping cessation outcomes. This suggests that treatment effectiveness for nicotine vaping doesn’t diminish substantially due to other common forms of substance use amongst young people.

However, the research found that varenicline treatment did not help participants reduce their cannabis use. Approximately 13% of those receiving varenicline achieved 30-day cannabis abstinence by week 12. This matched rates in other treatment groups. The medication proves helpful for youth vaping cessation specifically. It doesn’t function as a universal solution for all substance use.

Treatment Approaches and Programme Design

The study compared three different approaches. First was varenicline plus weekly behavioural counselling. Second was placebo plus behavioural counselling. Third was referral to a text messaging support programme. All participants received some form of support. This reflects current understanding that comprehensive approaches work best.

The behavioural counselling component involved weekly, remotely delivered individual sessions over 12 weeks. This format proved practical for young people whilst still providing meaningful support. The text messaging programme offered an even lower intensity option. However, it proved less effective than medication combined with counselling. The varenicline group achieved significantly higher abstinence rates than either alternative.

Implications for Youth Vaping Cessation Services

These findings carry several important implications. First, screening and treatment programmes for adolescent nicotine vaping treatment should not exclude young people who also use cannabis. Effective help remains available. The outcomes justify the effort.

Second, the research reinforces the value of evidence-based pharmacotherapy. Medication alone isn’t the complete answer. Yet varenicline proved substantially more effective than behavioural support alone. This held true regardless of cannabis use patterns. The adjusted odds ratios demonstrated consistent treatment effects across all cannabis use categories.

Third, the high prevalence of concurrent substance use amongst young people who vape highlights the importance of understanding these patterns. In this study, 72% reported cannabis use. Young people often don’t use substances in isolation. Effective support must account for this reality. Treatment programmes need to consider the full picture of adolescent substance use.

Study Limitations and Future Directions

The researchers acknowledged several limitations worth noting. Cannabis use was self-reported. This may be subject to recall bias. However, validated assessment tools were used. The Timeline Followback method captured detailed use patterns. The Cannabis Use Disorder Identification Test assessed severity.

The study may have lacked sufficient power to detect subtler interaction effects between treatment and cannabis use. Additionally, the research didn’t systematically assess how young people consumed cannabis. Different methods (smoking, vaping, edibles) might influence outcomes. The sample was limited to youth motivated to try reducing or quitting nicotine vaping. It excluded those who regularly smoked combusted tobacco.

Perhaps most importantly, participants weren’t seeking treatment for cannabis use. They enrolled specifically to address nicotine vaping. No behavioural support for reducing cannabis was provided. Future research might examine whether integrated interventions targeting both substances simultaneously could yield additional benefits. Some young people might benefit from comprehensive programmes addressing multiple substance use patterns.

Moving Forward with Youth Vaping Cessation

This research represents an important step in understanding how to support young people struggling with nicotine vaping. The findings suggest that effective youth vaping cessation treatment remains available even when other substance use is present. However, this shouldn’t diminish concerns about the risks any substance use poses to young people. The developing brain remains vulnerable during crucial developmental periods.

For families, educators, and health professionals, these findings offer reassurance that help can work. They also highlight the ongoing need for prevention efforts. The ultimate goal remains supporting young people to avoid substance use entirely. When intervention becomes necessary, effective options exist. The study provides evidence that treatment works across diverse patterns of substance use.

The study’s authors emphasise the urgent need to increase treatment availability for youth vaping cessation amongst adolescents and young adults. Nicotine vaping is now the most common form of nicotine use in this age group. Many young people develop patterns of regular use associated with addiction. Accessible and effective treatment becomes increasingly critical.

The reality is that young people face complex pressures around substance use, and they deserve access to treatments that work. This study shows we can offer genuine help, even when the situation seems complicated by multiple substances.

Source: jamanetwork